Want to see YARW full AI Analyst Report?
YARW Stock Chart & Stats
$30.21
$0.09(0.20%)
At close: 4:00 PM EDT
$30.21
$0.09(0.20%)
Day’s Range― - ―
52-Week Range$14.65 - $46.97
Previous CloseN/A
Volume2.93K
Average Volume (3M)31.83K
Market Cap
$75.93M
Enterprise Value$0.63
Total Cash (Recent Filing)$22.93M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield66.31%
Share Statistics
EPS (TTM)-23.45
Shares Outstanding2,669,746
10 Day Avg. Volume36,937
30 Day Avg. Volume31,826
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.89
Price to Sales (P/S)43.53
P/FCF Ratio-0.75
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$57.00Price Target Upside88.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-76
Revenue Forecast (FY)$350.00K
Bulls Say, Bears Say
Bulls Say
Low LeverageAn essentially debt-free balance sheet limits interest obligations and reduces leverage-related financial risk while the company funds clinical development. Positive equity provides a capital base, although continued losses mean this strength depends on controlling burn and preserving resources.
Clinical Pipeline Progress And Regulatory SupportAdvancing into Phase 2 with FDA Fast Track status creates a more developed clinical asset and may accelerate regulatory interaction for Graves’ disease and thyroid eye disease. Partner-led Phase 1 work also expands development activity across indications and geographies.
Newly Funded Growth PlatformThe completed financing materially supports Yarrow’s transition into a focused clinical-stage platform and provides capital to advance its pipeline. That funding can sustain research and development through important milestones, reducing immediate dependence on operating revenue that is not yet established.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow means the company cannot currently fund development from internal cash generation. Continued clinical investment therefore requires external capital, making financing access and disciplined spending important to maintaining the pipeline over the next several quarters.
Severe Operating Losses And Limited Revenue ScaleRevenue remains far too small to absorb the company’s operating expense base, leaving clinical progress disconnected from current profitability. Although reported revenue growth was positive, the low starting base and severe losses indicate that commercialization or other recurring revenue is still needed to improve financial sustainability.
Substantial Potential DilutionThe large warrant position relative to current common shares creates meaningful potential dilution and can alter future ownership and control as exercises occur. The subsequent offering also reinforces reliance on equity financing, which may increase the share base while funding ongoing clinical losses.
Yarrow Bioscience News
YARW FAQ
What was Yarrow Bioscience’s price range in the past 12 months?
Yarrow Bioscience lowest stock price was $14.65 and its highest was $46.97 in the past 12 months.
What is Yarrow Bioscience’s market cap?
Yarrow Bioscience’s market cap is $75.93M.
When is Yarrow Bioscience’s upcoming earnings report date?
Yarrow Bioscience’s upcoming earnings report date is Nov 05, 2026 which is in 54 days.
How were Yarrow Bioscience’s earnings last quarter?
Yarrow Bioscience released its earnings results on Aug 13, 2026. The company reported -$2.14 earnings per share for the quarter.
Is Yarrow Bioscience overvalued?
According to Wall Street analysts Yarrow Bioscience’s price is currently Undervalued.
Does Yarrow Bioscience pay dividends?
Yarrow Bioscience pays a Notavailable dividend of $20.1 which represents an annual dividend yield of 66.31%. See more information on Yarrow Bioscience dividends here
What is Yarrow Bioscience’s EPS estimate?
Yarrow Bioscience’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Yarrow Bioscience have?
Yarrow Bioscience has 2,669,746 shares outstanding.
What happened to Yarrow Bioscience’s price movement after its last earnings report?
Yarrow Bioscience reported an EPS of -$2.14 in its last earnings report. Following the earnings report the stock price went down -0.117%.
Which hedge fund is a major shareholder of Yarrow Bioscience?
Currently, no hedge funds are holding shares in YARW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Yarrow Bioscience Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$57.00 (88.68% Upside)
$57.00 (88.68% Upside)
Hedge Fund Trend
Decreased
By 24.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 2.0%
Last 30 Days ▼ 6.5%
Last 30 Days ▼ 6.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
203.31%
12-Months-Change
Fundamentals
Return on Equity
66.31%
Trailing 12-Months
Asset Growth
-47.22%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Yarrow Bioscience
Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).
YARW Stock 12 Month Forecast
Average Price Target
$57.00
▲(88.68% Upside)
Technical Analysis
Ownership Overview
57.81% Insiders
28.57% Mutual Funds
― Other Institutional Investors
13.41% Public Companies and
Individual Investors